FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000812251> ?p ?o ?g. }

• W2000812251 endingPage "211" @default.
• W2000812251 startingPage "199" @default.
• W2000812251 abstract "Background The use of mineralocorticoid receptor blockers (MRBs) in patients with chronic kidney disease is growing, but data for efficacy in decreasing proteinuria are limited by a relative paucity of studies, many of which are small and uncontrolled. Study Design We performed a systematic review using the MEDLINE database (inception to November 1, 2006), abstracts from national meetings, and selected reference lists. Setting & Population Adult patients with chronic kidney disease and proteinuria. Selection Criteria for Studies English-language studies investigating the use of MRBs added to long-term angiotensin-converting enzyme (ACE)-inhibitor and/or angiotensin receptor blocker (ARB) therapy in adult patients with proteinuric kidney disease. Intervention MRBs as additive therapy to conventional renin-angiotensin-aldosterone system blockade in patients with chronic kidney disease. Outcomes Changes in proteinuria as the primary outcome; rates of hyperkalemia, changes in blood pressure, and changes in glomerular filtration rate as secondary outcomes. Results 15 studies met inclusion criteria for our review; 4 were parallel-group randomized controlled trials, 4 were crossover randomized controlled trials, 2 were pilot studies, and 5 were case series. When MRBs were added to ACE-inhibitor and/or ARB therapy, the reported proteinuria decreases from baseline ranged from 15% to 54%, with most estimates in the 30% to 40% range. Hyperkalemic events were significant in only 1 of 8 randomized controlled trials. MRB therapy was associated with statistically significant decreases in blood pressure and glomerular filtration rate in approximately 40% and 25% of included studies, respectively. Limitations Reported results were insufficient for meta-analysis, with only 2 studies reporting sufficient data to calculate SEs of their published estimates. We were unable to locate studies that showed no effect of MRB treatment over placebo, raising concern for publication bias. Conclusions Although data suggest that adding MRBs to ACE-inhibitor and/or ARB therapy yields significant decreases in proteinuria without adverse effects of hyperkalemia and impaired renal function, routine use of MRBs as additive therapy in patients with chronic kidney disease cannot be recommended yet. However, the findings of this review promote interesting hypotheses for future study. The use of mineralocorticoid receptor blockers (MRBs) in patients with chronic kidney disease is growing, but data for efficacy in decreasing proteinuria are limited by a relative paucity of studies, many of which are small and uncontrolled. We performed a systematic review using the MEDLINE database (inception to November 1, 2006), abstracts from national meetings, and selected reference lists. Adult patients with chronic kidney disease and proteinuria. English-language studies investigating the use of MRBs added to long-term angiotensin-converting enzyme (ACE)-inhibitor and/or angiotensin receptor blocker (ARB) therapy in adult patients with proteinuric kidney disease. MRBs as additive therapy to conventional renin-angiotensin-aldosterone system blockade in patients with chronic kidney disease. Changes in proteinuria as the primary outcome; rates of hyperkalemia, changes in blood pressure, and changes in glomerular filtration rate as secondary outcomes. 15 studies met inclusion criteria for our review; 4 were parallel-group randomized controlled trials, 4 were crossover randomized controlled trials, 2 were pilot studies, and 5 were case series. When MRBs were added to ACE-inhibitor and/or ARB therapy, the reported proteinuria decreases from baseline ranged from 15% to 54%, with most estimates in the 30% to 40% range. Hyperkalemic events were significant in only 1 of 8 randomized controlled trials. MRB therapy was associated with statistically significant decreases in blood pressure and glomerular filtration rate in approximately 40% and 25% of included studies, respectively. Reported results were insufficient for meta-analysis, with only 2 studies reporting sufficient data to calculate SEs of their published estimates. We were unable to locate studies that showed no effect of MRB treatment over placebo, raising concern for publication bias. Although data suggest that adding MRBs to ACE-inhibitor and/or ARB therapy yields significant decreases in proteinuria without adverse effects of hyperkalemia and impaired renal function, routine use of MRBs as additive therapy in patients with chronic kidney disease cannot be recommended yet. However, the findings of this review promote interesting hypotheses for future study." @default.
• W2000812251 created "2016-06-24" @default.
• W2000812251 creator A5020881383 @default.
• W2000812251 creator A5058219520 @default.
• W2000812251 creator A5078458815 @default.
• W2000812251 creator A5080521060 @default.
• W2000812251 date "2008-02-01" @default.
• W2000812251 modified "2023-10-16" @default.
• W2000812251 title "Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review" @default.
• W2000812251 cites W1964028794 @default.
• W2000812251 cites W1965883240 @default.
• W2000812251 cites W1968999388 @default.
• W2000812251 cites W1970209851 @default.
• W2000812251 cites W1971543621 @default.
• W2000812251 cites W1971680322 @default.
• W2000812251 cites W1975603373 @default.
• W2000812251 cites W1986215651 @default.
• W2000812251 cites W2000060059 @default.
• W2000812251 cites W2002087415 @default.
• W2000812251 cites W2002839070 @default.
• W2000812251 cites W2003508199 @default.
• W2000812251 cites W2007689247 @default.
• W2000812251 cites W2011720599 @default.
• W2000812251 cites W2011932878 @default.
• W2000812251 cites W2018901137 @default.
• W2000812251 cites W2019270553 @default.
• W2000812251 cites W2020811647 @default.
• W2000812251 cites W2024894304 @default.
• W2000812251 cites W2031187741 @default.
• W2000812251 cites W2036226118 @default.
• W2000812251 cites W2039784350 @default.
• W2000812251 cites W2039893332 @default.
• W2000812251 cites W2044049836 @default.
• W2000812251 cites W2044773944 @default.
• W2000812251 cites W2045372964 @default.
• W2000812251 cites W2056194572 @default.
• W2000812251 cites W2061018844 @default.
• W2000812251 cites W2072543770 @default.
• W2000812251 cites W2073062706 @default.
• W2000812251 cites W2074391878 @default.
• W2000812251 cites W2090526184 @default.
• W2000812251 cites W2090621492 @default.
• W2000812251 cites W2101948924 @default.
• W2000812251 cites W2109996890 @default.
• W2000812251 cites W2111945961 @default.
• W2000812251 cites W2118932957 @default.
• W2000812251 cites W2123778248 @default.
• W2000812251 cites W2127817669 @default.
• W2000812251 cites W2128859532 @default.
• W2000812251 cites W2132715232 @default.
• W2000812251 cites W2134338262 @default.
• W2000812251 cites W2141297458 @default.
• W2000812251 cites W2143144750 @default.
• W2000812251 cites W2147273166 @default.
• W2000812251 cites W2148959930 @default.
• W2000812251 cites W2152094259 @default.
• W2000812251 cites W2153585291 @default.
• W2000812251 cites W2163709605 @default.
• W2000812251 cites W2170880252 @default.
• W2000812251 cites W2323458614 @default.
• W2000812251 cites W2615684303 @default.
• W2000812251 cites W4231659835 @default.
• W2000812251 cites W4320300920 @default.
• W2000812251 doi "https://doi.org/10.1053/j.ajkd.2007.10.040" @default.
• W2000812251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18215698" @default.
• W2000812251 hasPublicationYear "2008" @default.
• W2000812251 type Work @default.
• W2000812251 sameAs 2000812251 @default.
• W2000812251 citedByCount "204" @default.
• W2000812251 countsByYear W20008122512012 @default.
• W2000812251 countsByYear W20008122512013 @default.
• W2000812251 countsByYear W20008122512014 @default.
• W2000812251 countsByYear W20008122512015 @default.
• W2000812251 countsByYear W20008122512016 @default.
• W2000812251 countsByYear W20008122512017 @default.
• W2000812251 countsByYear W20008122512018 @default.
• W2000812251 countsByYear W20008122512019 @default.
• W2000812251 countsByYear W20008122512020 @default.
• W2000812251 countsByYear W20008122512021 @default.
• W2000812251 countsByYear W20008122512022 @default.
• W2000812251 countsByYear W20008122512023 @default.
• W2000812251 crossrefType "journal-article" @default.
• W2000812251 hasAuthorship W2000812251A5020881383 @default.
• W2000812251 hasAuthorship W2000812251A5058219520 @default.
• W2000812251 hasAuthorship W2000812251A5078458815 @default.
• W2000812251 hasAuthorship W2000812251A5080521060 @default.
• W2000812251 hasConcept C126322002 @default.
• W2000812251 hasConcept C126894567 @default.
• W2000812251 hasConcept C134018914 @default.
• W2000812251 hasConcept C159641895 @default.
• W2000812251 hasConcept C168563851 @default.
• W2000812251 hasConcept C2778525890 @default.
• W2000812251 hasConcept C2778653478 @default.
• W2000812251 hasConcept C2779561371 @default.
• W2000812251 hasConcept C2780091579 @default.
• W2000812251 hasConcept C2908647359 @default.
• W2000812251 hasConcept C71924100 @default.
• W2000812251 hasConcept C84393581 @default.

• next